EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Conditionally Reprogrammed Patient-Derived Nasal Epithelial Cell Cultures for In Vitro Diagnostics and Pharmacological Profiling in Primary Ciliary Dyskinesia

Ruth M Urbantat iD, Anita Balázs iD, Kathrin Seidel, Marika Drescher, Ricarda Lange, Aditi Löwe iD, Tihomir Rubil iD, Julia Duerr iD, Jobst F Röhmel, Stephanie Thee iD, Mirjam Stahl iD, Marcus A Mall iD

Cells · 2026

DOI: 10.3390/cells15201871 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Ruth M Urbantat und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany. Hauptthemen laut MEDLINE: Epithelial Cells, Cellular Reprogramming, Nasal Mucosa, Ciliary Motility Disorders. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Federal Ministry of Research, Technology and Space, Eva Luise and Horst Köhler Foundation for People with Rare Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Air-liquid interface (ALI) cultures of patient-derived primary nasal epithelial cells (pNEC) can support diagnostics and in vitro phenotyping of primary ciliary dyskinesia (PCD); however, low cell yield remains a limitation. We aimed to establish and optimize conditionally reprogrammed cell (CRC) technology for pNEC from individuals with PCD and use it as a diagnostic tool for inconclusive cases and for pharmacological testing. Methods: pNEC from 36 individuals (8 healthy controls (HC), 26 PCD, 2 PCD candidates) were expanded using CRC and differentiated at ALI. Ciliary beat frequency (CBF), mucociliary transport velocity (MCTV), and culture morphology were assessed. Further, we assessed the effect of the β-receptor agonist clenbuterol on cilia function in pNEC of HC, PCD (DNAH11, CCDC40) and PCD candidates harboring biallelic DNAH1 variants.

Results

CRC expansion demonstrated a >90% success rate, yielding high cell counts (mean 9.65 × 106). Differentiation at ALI resulted in pseudostratified ciliated pNEC cultures. CBF was comparable between native and cultured pNEC. MCTV was significantly reduced in PCD vs. HC cultures (p < 0.0001). Clenbuterol significantly increased CBF in HC and DNAH1, but not in CCDC40 or DNAH11 cultures. MCTV was significantly increased in HC by clenbuterol treatment.

Conclusions

CRC technology provides a scalable platform for the expansion of pNEC that recapitulate in vivo ciliary function. By enabling genotype-specific pharmacological screening, CRC may serve as a tool for functional diagnostics and precision medicine in PCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial CellsCellular ReprogrammingNasal MucosaCiliary Motility DisordersHumansFemaleCiliaMaleAdultCells, CulturedClenbuterolCell DifferentiationChildAdolescent

Stichwörter der Autor:innen

DNAH1air-liquid interface culturesclenbuterolconditional reprogrammingdiagnostic testingpharmacological testingprecision medicineprimary ciliary dyskinesiaβ-agonists

Substanzen

Clenbuterol

Autor:innen und Institutionen

  • Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
  • German Center for Lung Research (DZL), Associated Partner Site, 13353 Berlin, Germany.
  • Berlin Institute of Health (BIH), 10117 Berlin, Germany.
  • German Center for Child and Adolescent Health (DZKJ), Partner Site Berlin, 13353 Berlin, Germany.
  • Department of Respiratory and Critical Care Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
  • Cluster of Excellence ImmunoPreCept, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.

ORCID-Profile: Ruth M Urbantat, Anita Balázs, Aditi Löwe, Tihomir Rubil, Julia Duerr, Stephanie Thee, Mirjam Stahl, Marcus A Mall

Förderung

  • Deutsche Forschungsgemeinschaft
  • Federal Ministry of Research, Technology and Space
  • Eva Luise and Horst Köhler Foundation for People with Rare Diseases
  • German Research Foundation
  • German Federal Ministry of Research Technology and Space
  • Berliner Sparkassenstiftung Medizin

Zitieren

APA

Urbantat, R. M., Balázs, A., Seidel, K., Drescher, M., Lange, R., Löwe, A., Rubil, T., Duerr, J., Röhmel, J. F., Thee, S., Stahl, M., & Mall, M. A. (2026). Conditionally Reprogrammed Patient-Derived Nasal Epithelial Cell Cultures for In Vitro Diagnostics and Pharmacological Profiling in Primary Ciliary Dyskinesia. Cells. https://doi.org/10.3390/cells15201871

Vancouver

Urbantat RM, Balázs A, Seidel K, Drescher M, Lange R, Löwe A, et al. Conditionally Reprogrammed Patient-Derived Nasal Epithelial Cell Cultures for In Vitro Diagnostics and Pharmacological Profiling in Primary Ciliary Dyskinesia. Cells. 2026. doi:10.3390/cells15201871

BibTeX
@article{Urbantat2026,
  author = {Urbantat, Ruth M and Balázs, Anita and Seidel, Kathrin and Drescher, Marika and Lange, Ricarda and Löwe, Aditi and Rubil, Tihomir and Duerr, Julia and Röhmel, Jobst F and Thee, Stephanie and Stahl, Mirjam and Mall, Marcus A},
  title = {Conditionally Reprogrammed Patient-Derived Nasal Epithelial Cell Cultures for In Vitro Diagnostics and Pharmacological Profiling in Primary Ciliary Dyskinesia},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15201871}
}
Kostenlos starten →